Ibrance Combo Fails 1,000-Patient Trial; Dermatitis Antibody, Eczema Therapy Advance
Ibrance combined with Roche’s giredestrant failed to improve progression-free survival in a 1,000-patient late-stage breast-cancer trial, threatening its CHF1.2 billion peak sales forecast. Pfizer’s Phase 2 trispecific antibody succeeded in moderate-to-severe atopic dermatitis and its eczema therapy met a mid-stage goal, moving into late-stage trials.
1. Ibrance Combination Misses Primary Endpoint
The combination of Roche’s giredestrant with Pfizer’s Ibrance failed to meet its primary progression-free survival goal in a late-stage study of nearly 1,000 women with advanced ER-positive breast cancer. This setback challenges plans to expand Ibrance’s label and may jeopardize a previously estimated CHF1.2 billion peak annual sales opportunity.
2. Positive Phase 2 Results for Trispecific Antibody
Pfizer’s trispecific antibody targeting moderate-to-severe atopic dermatitis met all primary and key secondary endpoints in a Phase 2 trial, showing significant skin clearance and itch reduction. The safety profile aligned with expectations, positioning the program for further development in a pivotal study.
3. Eczema Therapy Advances to Late-Stage Testing
An investigational eczema drug from Pfizer achieved its main efficacy objective in a mid-stage trial, delivering meaningful reductions in lesion severity scores versus placebo. Pfizer plans to launch late-stage trials later this year to validate these findings in a larger patient population.